Full-Time

Senior Manager

Performance Analytics and Insights

Posted on 9/16/2025

Deadline 9/27/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$120.8k - $201.4k/yr

+ Bonus

No H1B Sponsorship

Phoenixville, PA, USA + 2 more

More locations: Highland Park, IL, USA | New York, NY, USA

Hybrid

Flexible work location; 2-3 days onsite per week.

Category
Business & Strategy (2)
,
Required Skills
Python
Data Science
R
SQL
Tableau
Looker
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Fluent in English (written and spoken)
  • Strong coding skills (such as: Python, R, SQL, etc.), MS Excel and PowerPoint skills
  • Deep understanding of data visualization tools and experience designing and building complex dashboards, including but not limited to Tableau, PowerBI, Qlik and Looker
  • Strong reporting and analytical skills to be able to synthesize and validate various inputs, and ability to communicate 'the story' to commercial leadership
  • Extensive experience in the design and management of secondary data analytics
  • Ability to assess and direct vendor technical capabilities and manage risks in the analytic process
  • Ability to be flexible, prioritize multiple demands, deal with ambiguity, and lead teams through complex and challenging cross-functional projects
  • Recognized expertise and coach to others on connecting, integrating, and synthesizing analysis into a meaningful 'so what' to drive clear strategic recommendations and enable commercial decision making
  • Proven ability to act as a strategic partner with the capacity to quickly establish relationships of trust, credibility, and be seen as a driving partner to senior leadership
  • Ability to identify, prioritize and describe relevant caveats and uncertainties in data, including how they relate to the business question and broader strategic priorities
  • Previous demonstrated Business / Financial acumen
Responsibilities
  • Support the build and standardization of commercial reporting eco-system
  • Act as strategic partner to frame, investigate, and answer key business questions related to organization wide performance reporting, including executive reporting
  • Lead identification of information needs and development of project plans to address those needs
  • Develop and execute creation of in-house dataset to drive patient and HCP insights into infrastructure of care
  • Connect reporting insights together to tell a compelling and persuasive story and deliver clear and actionable recommendations to senior leadership
  • Support dialogue to adapt global strategies and standardization of performance metrics and tracking
  • Actively contribute to advancement of capabilities through thought leadership; seek to share knowledge and expertise with other colleagues making use of knowledge sharing platform
  • Alignment with other GCA teams to ensure cohesive activities with our stakeholders
  • Partner with other analytic functions to advance the use of novel data sources and reporting, including RWD, Data Science, etc.
  • Ensure team commissioning and contracting through preferred vendors
  • Accountable for team meeting compliance and Corporate SOP obligations of all primary market research projects
  • Direct workload of flexible resources
  • Be accountable for continuous improvement and identification/utilization of new capabilities to maximize the competitive advantages of the business
Desired Qualifications
  • Experience of leveraging AI/GenAI is preferred
  • Previous demonstrated experience in using innovative techniques to monitor, simulate and analyze complex data sets preferred

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE